Spontaneous Regression of Focal Nodular Hyperplasia of the Liver after Delivery: A Case Report

A focal nodular hyperplasia (FNH) of the liver is the second most common benign hepatic tumor, but an interval growth or regression of FNH is uncommon. We report a case of spontaneous regression of FNH in a 34-year-old woman. This lesion was diagnosed during pregnancy and spontaneously regressed during a 5-year observation period after delivery.

Index terms
Focal Nodular Hyperplasia
Spontaneous Regression
Pregnant Woman

INTRODUCTION

A focal nodular hyperplasia (FNH) is a proliferation of non-neoplastic hepatocytes that is believed to be a local hyperplastic response to a vascular abnormality (1). It is the second most common benign hepatic tumor and most commonly incidentally found in women in their 3rd and 4th decades of life (2). Female hormones have been suggested by clinical observations to play a role because of the female predominance and the young age at onset (1, 3), but it is not clear whether there is an association between FNH and oral contraceptive (OC) or pregnancy. The natural history of FNH is still unknown, because long term follow-up studies of histologically proven FNH with conflicting results have been performed only in small series of patients (4-6). Herein, we report a patient with FNH of the liver, which was diagnosed during pregnancy and spontaneously regressed during a 5-year observation period after delivery.

CASE REPORT

A 34-year-old pregnant woman at 17 weeks and 3 days of gestation presented with hyperemesis gravidarum. The patient was multiparous (T3 P0 A1) and had no remarkable medical history. On admission, her physical examination was unremarkable except her pregnant state. Laboratory data including liver function test, hepatitis viral markers and tumor markers were within normal limits except a slightly elevated serum bilirubin level. The patient had no history of OCs use or estrogen therapy.

A transabdominal ultrasound examination demonstrated a 4 cm sized isoechoic solid mass in the IV segment of the liver. The color Doppler revealed blood flow around and within the mass. The initial differential diagnosis included FNH and hepatocellular adenoma. But it was not possible to perform contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) because of her pregnant state.

At the 32th week of pregnancy, the patient underwent cesarean section due to refractory severe hyperemesis gravidarum. A
Spontaneous Regression of Focal Nodular Hyperplasia of the Liver after Delivery

dynamic abdominal CT was performed five days after the delivery. The pre-contrast CT scan showed a 4 cm sized, low density mass arising from segment IV of the liver. The mass was well enhanced on the arterial phase of CT scan. On the portal and delayed phases, the mass showed slightly low attenuation compared with the surrounding liver parenchyma. No central scar was noted on the CT images (Fig. 1).

A MRI was performed with a clinical 1.5-T unit (Signa HDx; GE Healthcare, Waukesha, WI, USA) with contrast enhancement (MultiHance; Bracco Diagnostics, Lake Success, NY, USA) (Fig. 2).

**Fig. 1.** A dynamic abdominal CT scan acquired five days after the delivery. 
A. Precontrast CT scan shows a 4.2 × 4.0 cm size, well defined exophytic growing low density mass arising from segment IV of liver. 
B. C. On arterial phase, the mass is well enhanced (B), and shows slightly low attenuation compared with the surrounding liver parenchyma on portal phase (C).

**Fig. 2.** Liver MRI using hepatocyte-specific contrast agent. 
A. A T2-weighted imaging shows the high SI mass at segment IV. 
B. Following intravenous administration of gadobenate dimeglumine, an arterial phase T1-weighted imaging (T1WI) shows an intensely enhancing mass with a nonenhancing central scar (arrow). 
C. Portal phase image shows that the mass is isointense with the liver parenchyma and the central scar enhancing. 
D. A hepatobiliary phase T1WI shows an isointense mass with a hypointense central scar (arrow).
been controversial discussed (5, 7). In addition, the course of FNH during pregnancy has not yet been studied in detail. But existing reports have mostly been showing a benign course of FNH during pregnancy; Mathieu et al. (5) described 12 patients with FNH that did not change in size during uneventful pregnancies. Cobey and Salem (8) summarized available data showing the growth progression of FNH during pregnancy in 1 out of 32 women only. Rifai et al. (9) described no substantial growth in 20 patients and no complications during pregnancy or birth in all 16 patients who responded to their questionnaire.

There have been conflicting results regarding the natural history of FNH. Although the majority of studies showed that an interval growth of FNH is uncommon, there are occasional reports of FNH cases with interval regression (5, 10). Mathieu et al. (5) followed 216 patients for 9 years and showed a size change of FNH in 4 of 136 patients only (3%). Among them, 3 cases showed interval regression and 1 showed interval growth.

In our case, the patient was diagnosed with FNH in pregnancy. Because the FNH was found incidentally during her pregnancy, we didn’t know whether the pregnancy had influenced the FNH or not. At least, the size of the FNH was not changed on the follow-up CT images performed a few days after the delivery. The patient and her physician decided to conservatively follow-up because the FNH was confirmed on MRI and microscopic findings after the delivery. Also, the FNH regressed significantly during the 5-year follow-up after delivery. The patient had no history of exogenous estrogen use prior to the initial diagnosis of FNH and didn’t have any therapy between her initial presentation and the last follow-up. There is neither sufficient

DISCUSSION

FNH of the liver is a benign tumor-like lesion that is typically discovered by incidence during diagnostic imaging performed for other reasons. Some have speculated that hormones play a role in the pathogenesis of the tumor because FNH typically occurs in female of reproductive age and about 50–75% of patients with FNH are OCs users (2). Although endogenous or exogenous estrogens clearly play a role in the pathogenesis of hepatic adenoma, their relationship with focal nodular hyperplasia has been controversial discussed (5, 7). In addition, the course of FNH during pregnancy has not yet been studied in detail. But existing reports have mostly been showing a benign course of FNH during pregnancy; Mathieu et al. (5) described 12 patients with FNH that did not change in size during uneventful pregnancies. Cobey and Salem (8) summarized available data showing the growth progression of FNH during pregnancy in 1 out of 32 women only. Rifai et al. (9) described no substantial growth in 20 patients and no complications during pregnancy or birth in all 16 patients who responded to their questionnaire.

There have been conflicting results regarding the natural history of FNH. Although the majority of studies showed that an interval growth of FNH is uncommon, there are occasional reports of FNH cases with interval regression (5, 10). Mathieu et al. (5) followed 216 patients for 9 years and showed a size change of FNH in 4 of 136 patients only (3%). Among them, 3 cases showed interval regression and 1 showed interval growth.

In our case, the patient was diagnosed with FNH in pregnancy. Because the FNH was found incidentally during her pregnancy, we didn’t know whether the pregnancy had influenced the FNH or not. At least, the size of the FNH was not changed on the follow-up CT images performed a few days after the delivery. The patient and her physician decided to conservatively follow-up because the FNH was confirmed on MRI and microscopic findings after the delivery. Also, the FNH regressed significantly during the 5-year follow-up after delivery. The patient had no history of exogenous estrogen use prior to the initial diagnosis of FNH and didn’t have any therapy between her initial presentation and the last follow-up. There is neither sufficient

![Fig. 3. On follow-up CT scan acquired 5 years later, the focal nodular hyperplasia is measured 0.8 × 1.0 cm. This lesion still shows intense enhancement on the arterial phase (A) and iso-density on the portal phase (B).](https://example.com/fig3.png)
data to conclude that the natural history of our patient’s lesion can be attributed to her delivery nor is there sufficient data to conclude otherwise.

The correlation between the natural history of FNH and pregnancy/delivery remains unclear with some conflicting data and cases of postpartum long term follow-up are very rare. Therefore, further study is necessary to firmly establish the role of pregnancy and delivery in the natural history of FNH. A case-control or prospective cohort study with long term follow-up could potentially provide resolution.

REFERENCES


분만 후 자발성 퇴행을 보인 간의 국소결절성과증식: 증례 보고

임영식1·이민희1·최서연1·이범하1·이혜경1·김희경2

간의 국소결절성과증식은 무증상으로 우연히 발견되는 흔한 양성 병변이나 자발적인 크기 변화는 흔하지 않다. 저자들은 34세 여자 환자에서 임신 기간 중 우연히 발견된 국소결절성과증식이 분만 후 5년간 추적 검사에서 자발적으로 퇴행된 증례를 경험하였다. 이에 문헌 고찰과 함께 보고하고자 한다.

순천향대학교 의과대학 부천병원 1영상의학과, 2병원과